ACB
Price
$4.54
Change
+$0.07 (+1.57%)
Updated
Jul 3 closing price
Capitalization
238.86M
32 days until earnings call
EVO
Price
$4.20
Change
-$0.14 (-3.23%)
Updated
Jul 3 closing price
Capitalization
2.77B
38 days until earnings call
Interact to see
Advertisement

ACB vs EVO

Header iconACB vs EVO Comparison
Open Charts ACB vs EVOBanner chart's image
Aurora Cannabis
Price$4.54
Change+$0.07 (+1.57%)
Volume$708.07K
Capitalization238.86M
Evotec SE
Price$4.20
Change-$0.14 (-3.23%)
Volume$61.99K
Capitalization2.77B
ACB vs EVO Comparison Chart in %
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. EVO commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and EVO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (ACB: $4.54 vs. EVO: $4.20)
Brand notoriety: ACB: Notable vs. EVO: Not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ACB: 58% vs. EVO: 42%
Market capitalization -- ACB: $238.86M vs. EVO: $2.77B
ACB [@Pharmaceuticals: Other] is valued at $238.86M. EVO’s [@Pharmaceuticals: Other] market capitalization is $2.77B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileEVO’s FA Score has 1 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • EVO’s FA Score: 1 green, 4 red.
According to our system of comparison, EVO is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 5 TA indicator(s) are bullish while EVO’s TA Score has 6 bullish TA indicator(s).

  • ACB’s TA Score: 5 bullish, 5 bearish.
  • EVO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, EVO is a better buy in the short-term than ACB.

Price Growth

ACB (@Pharmaceuticals: Other) experienced а +6.57% price change this week, while EVO (@Pharmaceuticals: Other) price change was -0.47% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.02%. For the same industry, the average monthly price growth was +2.94%, and the average quarterly price growth was +92.60%.

Reported Earning Dates

ACB is expected to report earnings on Aug 07, 2025.

EVO is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.02% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EVO($2.77B) has a higher market cap than ACB($239M). ACB YTD gains are higher at: 6.824 vs. EVO (0.962). EVO has higher annual earnings (EBITDA): -63.26M vs. ACB (-1.64B). EVO has more cash in the bank: 619M vs. ACB (149M). ACB has less debt than EVO: ACB (103M) vs EVO (589M). EVO has higher revenues than ACB: EVO (821M) vs ACB (212M).
ACBEVOACB / EVO
Capitalization239M2.77B9%
EBITDA-1.64B-63.26M2,588%
Gain YTD6.8240.962710%
P/E RatioN/A476.19-
Revenue212M821M26%
Total Cash149M619M24%
Total Debt103M589M17%
FUNDAMENTALS RATINGS
ACB vs EVO: Fundamental Ratings
ACB
EVO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8994
PRICE GROWTH RATING
1..100
6250
P/E GROWTH RATING
1..100
842
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACB's Valuation (55) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVO (93) in the null industry. This means that ACB’s stock grew somewhat faster than EVO’s over the last 12 months.

ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as EVO (100) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.

ACB's SMR Rating (89) in the Pharmaceuticals Other industry is in the same range as EVO (94) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.

EVO's Price Growth Rating (50) in the null industry is in the same range as ACB (62) in the Pharmaceuticals Other industry. This means that EVO’s stock grew similarly to ACB’s over the last 12 months.

EVO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for ACB (84) in the Pharmaceuticals Other industry. This means that EVO’s stock grew significantly faster than ACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBEVO
RSI
ODDS (%)
Bullish Trend 4 days ago
85%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
72%
Momentum
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
67%
MACD
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
64%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 5 days ago
68%
Declines
ODDS (%)
Bearish Trend 17 days ago
88%
Bearish Trend 17 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
85%
Aroon
ODDS (%)
Bullish Trend 4 days ago
57%
Bearish Trend 4 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SGFFX51.260.60
+1.18%
Sparrow Growth A
JFDRX19.440.20
+1.04%
JHancock Financial Industries R6
GQGRX17.600.11
+0.63%
GQG Partners Emerging Markets Equity R6
PASRX20.460.11
+0.54%
Putnam Dynamic Asset Allocation Gr R
TIQIX30.940.06
+0.19%
Touchstone Non-US Equity Y

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been loosely correlated with CGC. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
+1.57%
CGC - ACB
63%
Loosely correlated
+7.56%
OGI - ACB
60%
Loosely correlated
+3.62%
CRON - ACB
56%
Loosely correlated
+2.00%
TLRY - ACB
55%
Loosely correlated
+11.03%
CRDL - ACB
35%
Loosely correlated
+10.79%
More

EVO and

Correlation & Price change

A.I.dvisor tells us that EVO and OGI have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EVO and OGI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
-3.23%
OGI - EVO
26%
Poorly correlated
+3.62%
ESPR - EVO
25%
Poorly correlated
+1.74%
CGC - EVO
24%
Poorly correlated
+7.56%
ACB - EVO
23%
Poorly correlated
+1.57%
ELAN - EVO
22%
Poorly correlated
-0.54%
More